RT Journal Article SR Electronic T1 Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.08.09.21261290 DO 10.1101/2021.08.09.21261290 A1 Peter B. Gilbert A1 David C. Montefiori A1 Adrian McDermott A1 Youyi Fong A1 David C. Benkeser A1 Weiping Deng A1 Honghong Zhou A1 Christopher R. Houchens A1 Karen Martins A1 Lakshmi Jayashankar A1 Flora Castellino A1 Britta Flach A1 Bob C. Lin A1 Sarah O’Connell A1 Charlene McDanal A1 Amanda Eaton A1 Marcella Sarzotti-Kelsoe A1 Yiwen Lu A1 Chenchen Yu A1 Bhavesh Borate A1 Lars W. P. van der Laan A1 Nima Hejazi A1 Chuong Huynh A1 Jacqueline Miller A1 Hana M. El Sahly A1 Lindsey R. Baden A1 Mira Baron A1 Luis De La Cruz A1 Cynthia Gay A1 Spyros Kalams A1 Colleen F. Kelley A1 Mark Kutner A1 Lawrence Corey A1 Kathleen M. Neuzil A1 Lindsay N. Carpp A1 Rolando Pajon A1 Dean Follmann A1 Ruben O. Donis A1 Richard A. Koup A1 on behalf of the Immune Assays; Moderna, Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); and United States Government (USG)/CoVPN Biostatistics Teams YR 2021 UL http://medrxiv.org/content/early/2021/08/12/2021.08.09.21261290.abstract AB Background In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.Methods Through case-cohort sampling, participants were selected for measurement of four serum antibody markers at Day 1 (first dose), Day 29 (second dose), and Day 57: IgG binding antibodies (bAbs) to Spike, bAbs to Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers calibrated to the WHO International Standard (cID50 and cID80). Participants with no evidence of previous SARS-CoV-2 infection were included. Cox regression assessed in vaccine recipients the association of each Day 29 or 57 serologic marker with COVID-19 through 126 or 100 days of follow-up, respectively, adjusting for risk factors.Results Day 57 Spike IgG, RBD IgG, cID50, and cID80 neutralization levels were each inversely correlated with risk of COVID-19: hazard ratios 0.66 (95% CI 0.50, 0.88; p=0.005); 0.57 (0.40, 0.82; p=0.002); 0.42 (0.27, 0.65; p<0.001); 0.35 (0.20, 0.61; p<0.001) per 10-fold increase in marker level, respectively, multiplicity adjusted P-values 0.003-0.010. Results were similar for Day 29 markers (multiplicity adjusted P-values <0.001-0.003). For vaccine recipients with Day 57 reciprocal cID50 neutralization titers that were undetectable (<2.42), 100, or 1000, respectively, cumulative incidence of COVID-19 through 100 days post Day 57 was 0.030 (0.010, 0.093), 0.0056 (0.0039, 0.0080), and 0.0023 (0.0013, 0.0036). For vaccine recipients at these titer levels, respectively, vaccine efficacy was 50.8% (− 51.2, 83.0%), 90.7% (86.7, 93.6%), and 96.1% (94.0, 97.8%). Causal mediation analysis estimated that the proportion of vaccine efficacy mediated through Day 29 cID50 titer was 68.5% (58.5, 78.4%).Conclusions Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy and likely have utility in predicting mRNA-1273 vaccine efficacy against COVID-19.Trial registration number COVE ClinicalTrials.gov number, NCT04470427Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/downloads/coi_disclosure.docx and declare: P.B.G., D.C.M., Y.F., C.M., A.E., M.S.-K., Y.L., C.Y., B.B., L.v.d.L., H.M.E.S., L.R.B., M.B., C.F.K., L.C., and L.N.C. had support (in the form of grant payments to their institution) from the National Institutes of Health for the submitted work; R.A.K. had support (in the form of funds to the VRC to cover assay performance) from the National Institutes of Health for the submitted work; M.B., L.D.L.C., and C.F.K. had support (in the form of payments to their institution) from Moderna for the submitted work; W.D., H.Z., J.M., and R.P. are employed by Moderna Tx, Inc. and have stock and/or stock options in Moderna Tx, Inc.; L.R.B. declares support (in the form of grant payments to his institution) within the previous three years from the National Institutes of Health, the Wellcome Trust, and the Bill and Melinda Gates Foundation and has served on NIAID-NIH SMCs within the previous three years; M.B. declares support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health and the Centers for Disease Control; C.F.K. declares support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health, the Centers for Disease Control, Humanigen, Novavax, Viiv, and Gilead, as well as payments from Medscape and from Clinical Care Options within the previous three years for educational events; K.M.N. declares support (in the form of grant payments to her institution) within the previous three years from GSK, Pfizer, Bill & Melinda Gates Foundation, and PATH for vaccine research, as well as support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health for influenza vaccine research. All other authors declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialCOVE ClinicalTrials.gov number, NCT04470427Funding StatementSupported by Public Health Service Grant UM1 AI068635 to the HVTN Statistical Data and Management Center [SDMC], Fred Hutchinson Cancer Research Center [FHCRC] from the National Institute of Allergy and Infectious Diseases (NIAID) and by the Intramural Research Program of the NIAID. This work was also supported by Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034, and Moderna, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The mRNA-1273-P301 study is being conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, and applicable government regulations. The Central Institutional Review Board approved the mRNA-1273-P301 protocol and the consent forms. All participants provided written informed consent before enrollment. Central IRB services for the mRNA-1273-P301 study were provided by Advarra, Inc., 6100 Merriweather Dr., Suite 600, Columbia, MD 21044.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs the trial is ongoing, access to patient-level data and supporting clinical documents with qualified external researchers may be available upon request and subject to review once the trial is complete.